Overview
OpenEvidence has raised $200M in a Venture round on Oct 20, 2025, with participation from GV. The company the leading medical information platform. The round will be used to accelerate product development, expand the team, and scale go-to-market operations.
Operating in the software development sector, OpenEvidence is positioned to capitalize on growing demand for innovative solutions in this space. With fresh capital, the company is expected to invest heavily in R&D and talent acquisition, signaling a period of aggressive growth ahead.
Market Outlook
This funding positions OpenEvidence as one to watch in the software development landscape. As the company scales, it will likely become an increasingly attractive partner — and customer — for B2B vendors looking to sell into well-funded, growth-stage companies. The post-raise window of 60-90 days is typically when startups are most receptive to new tools, services, and partnerships.
Why contact OpenEvidence now
OpenEvidence just closed $200M in Venture funding — which means they're actively scaling their team, upgrading their tech stack, and looking for vendors who can help them move fast. Companies at this stage typically make purchasing decisions within 60-90 days of closing a round. If you sell to software development companies, this is your window to reach out before competitors do.
Founders & Contacts
Investors
Company Facts
| Company | OpenEvidence |
| Amount Raised | $200M |
| Funding Round | Venture |
| Date Raised | Oct 20, 2025 |
| Founded | 2021 |
| Industry | Software Development |
| Founders |
Get Verified Founder Emails
Access verified email addresses and contact details for OpenEvidence's founders and thousands of other funded startups.
Start Free Trial